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Abstract
Background: Cryptosporidium spp. is a ubiquitous parasite affecting humans as well as domestic and wild vertebrates,
causing diarrhea in both immunocompetent and immunocompromised hosts worldwide. Its transmission occurs
primarily by the fecal-oral route. In humans, C. parvum and C. hominis are the most prevalent species, whereas
immunocompetent and immunocompromised individuals can also be infected by other zoonotic species. Renal
transplant patients are prone to develop cryptosporidiosis, which can induce severe and life-threatening diarrhea.
Case presentation: We report here a series of nearly concomitant cases of acute symptomatic cryptosporidiosis
in three renal transplant patients attending the Strasbourg University Hospital Nephrology Unit. The clinical
presentation was persistent diarrhea and acute renal failure. The diagnosis was confirmed by microscopic stool
examination using a modified Ziehl-Neelsen staining method and species identification by molecular tools. All
patients were treated with nitazoxanide and recovered from diarrhea after 14 days of therapy.
Conclusion: Genotypic species identification was not consistent with an epidemic context, thus underlining the
need for genotyping to monitor at risk patients.
Keywords: Cryptosporidium, Renal transplant, Zoonotic species, Genotypic species identification, Case report
Background
The coccidian protozoan Cryptosporidium spp. is an
intestinal parasite and a significant cause of enteric dis-
ease in humans and numerous other vertebrates world-
wide. Cryptosporidiosis is the most common zoonotic
cause of human parasitic diarrhea (i.e., 60 % of epidemic
cases linked to waterborne and 2–6 % of cases involving
severe diarrhea worldwide), especially in immunocom-
promised individuals and young children [1]. The latter
is notably the case in developing countries, where this
parasite ranks second in the causes of death in children
under 2 years [1, 2]. The prevalence of Cryptosporidium
in stools of immucompetent persons was found to be
lower in high-income countries than in developing re-
gions [3]. Infection occurs by oocyst-stage ingestion via
contaminated drinking water, food or recreational wa-
ters, as well as by direct or indirect human-to-human or
animal-to-human contact [4]. In France, 407 cases of
cryptosporidiosis were diagnosed between 2006 and 2009
[5]. A study conducted by the Strasbourg University
Hospital between 2011 and 2013 detected Cryptospor-
idium spp. in 2.4 % of stools in which parasites have
been detected out of a total of 6515 analyzed stools [6].
Over the past 20 years, three cryptosporidiosis out-
breaks have been reported in France [5]. Other docu-
mented cases are linked to outdoor activity, swimming
pools, day-care centers, and travel [3, 7]. Cryptosporidi-
osis can spread also among hospitalized patients and
hospital staff and nosocomial outbreak of Cryptosporid-
ium have been described. Source of infection could be
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contaminated water or contact with the hands of in-
fected people [8, 9].
The increasing frequency of human cryptosporidiosis
outbreaks raises relevant public health and economic
concerns [10–12]. Human cases are commonly due to
two species: C. hominis, which primarily infects humans,
and C. parvum, which infects both humans and animals.
Occasional infections by other species/genotypes, such as
C. felis, C. meleagridis, C. canis or chipmunk and rabbit
genotypes have been primarily reported in immunodefi-
cient patients [5]. C. hominis and the zoonotic Cryptospor-
idium species are associated with a variety of clinical
manifestations in humans [13].
The severity and duration of human Cryptosporidium
infections are linked to the host’s immune status [14].
Immunocompetent patients experience self-limiting dis-
ease, while in immunosuppressed patients, especially
those with T-cell deficiency, cryptosporidiosis is often
chronic and severe with risks of extra-intestinal disease
development [15].
In renal transplant patients, post-transplant crypto-
sporidiosis with diarrhea is a frequent complication [16].
In France, 69.3 % of clinically apparent cryptosporidiosis
cases reported from 2006 to 2009 involved immunocom-
promised patients and 16.5 % of them were reported in
patients who had received solid-organ or stem-cell
transplants [5]. One report from a pediatric renal trans-
plant unit demonstrated that infections were the primary
cause of diarrhea, with Cryptosporidium spp. diagnosed
in 11 % of 199 cases [3].
We report here three Cryptosporidium spp. infections
with acute diarrhea and abdominal pain, observed al-
most simultaneously in three renal transplant patients
who were subject to species genotyping in order to in-
vestigate a potential epidemic context in an outpatient
nephrology unit.
Case presentation
The three cases were diagnosed in the outpatient unit of
the Nephrology Department at Strasbourg University
Hospital, France.
Clinical histories
Patient #1 was a 60-year-old man who underwent trans-
plantation at the age of 52 for chronic renal failure due
to polycystic kidney disease. He initially received im-
munosuppressive treatment, consisting of tacrolimus
(4 mg/day), mycophenolate mofetil (MMF) (1 g x 2/day),
and prednisone (7.5 mg/day). Eight years after renal
transplantation, he presented with watery diarrhea, nau-
sea and vomiting starting 15 days before consulting
(September 25th, 2014). Physical examination revealed
asthenia, weight loss (6Kg), hypotension, dry mouth, and
acute renal failure (glomerular filtration rate [GFR]:
30 ml/min/1.73 m2). The patient reported no recent
travel or contact with swimming pool water, non-
drinking water or farm animals, but admitted to own a
dog. No other family member experienced diarrhea.
Patient #2 was a 64-year-old man of Malian origin
who had lived in France for 40 years and undergone
transplantation at the age of 62 for chronic renal failure
secondary to glomerulonephritis. Immunosuppressive
treatment consisted of tacrolimus (7 mg x 2/day), MMF
(750 mg x 2/day), and prednisone (10 mg/day). Two
years and 4 months following renal transplantation, he
presented with watery diarrhea and abdominal pain
lasting for 15–20 days (starting September 26th, 2014).
Physical examination revealed weight loss (13Kg),
esophageal pain, and acute renal failure (GFR: 36 mL/
min/1.73 m2). The patient also presented leucopenia
and neutropenia, initially attributed to an overdose of
tacrolimus. He reported no previous contact with non-
drinking water, swimming pool water or farm animals,
but had travelled to Mali for 2 months shortly before
the onset of diarrhea. No other person of his family ex-
perienced diarrhea.
Patient #3 was a 34-year-old man of Kosovar origin
who underwent transplantation aged 24-year-old for an
undetermined reason. Acute transplant rejection 2 years
later led to a second transplantation in September, 2014.
Immunosuppressive treatment consisted of tacrolimus
(6 mg x 2/day), MMF (750 mg x 2/day), and prednisone
(25 mg/day). Ten days following the second renal trans-
plantation (September 21th, 2014), the patient exhibited
watery diarrhea and abdominal pain. Physical examin-
ation indicated weight loss (10Kg) and acute renal failure
(GFR: 16 ml/min/1.73 m2). The patient, who reported
no contact with non-drinking water, swimming pool
water or farm animals, had travelled to Kosovo for
1 month before transplantation. His 2-year-old daughter
also presented with diarrhea from an unknown cause
that lasted for 3 days. No stool analyses were done for
the daughter.
Parasitological investigations
For all three patients, stool examinations performed at
the first consultation revealed the presence of Cryptospor-
idium oocysts, using a modified Ziehl-Neelsen staining
method (5–10 oocysts/slide, >100 oocysts/slide, and 1–5
oocysts/slide for cases #1, #2, and #3, respectively). All
stool samples were negative for the bacteria Clostridium
difficile, Salmonella, Shigella but also for rotavirus and
norovirus, and for parasites Giardia and microsporidia.
DNA was extracted from the stool samples using a
NucliSENS easyMAG device (bioMérieux, Marcy l’Etoile,
France) [17]. Briefly, it consisted of adding 400 mg of stool
samples to 1 mL of NucliSENS lysis buffer in a tube con-
taining ceramic beads (lysing matrix D; MP Biomedicals,
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Illkirch, France), disrupted in a FastPrep-24 grinder (MP
Biomedicals) at maximum power for 1 min. After 10 min
of incubation at room temperature to ensure complete
lysis, the tubes were centrifuged at 10,000 × g for 10 min
and extraction was performed with 250 μL of supernatant.
Elution was performed at 70 °C with 100 μL of elution
buffer. An in-house real-time polymerase chain reaction
(PCR) assay was set up to enable the detection and
identification of the most common Cryptosporidium
species/genotypes [18]. To this end, we used a single
reaction tube with fluorescence-labelled probes for the
real-time detection of Cryptosporidium, in addition to
melting curve analyses of PCR products to differentiate
between the Cryptosporidium species/genotypes. We
conducted the amplification of a 258 bp DNA fragment
located in the 18S ribosomal ribonucleic acid (rRNA) gene
(GenBank accession n°L16996; positions 80 to 337) using
the following primers: Cry80F: 5’-GTTAAACTGCRAA
TGGCT-3’; Cry337R: 5’-CGTCATTGCCACGGTA-3’.
The CryAnch-labelled hybridization probe (5’-CCGTCTA
AAGCTGATAGGTCAGAAACTTGAATG-fluorescein-3’)
hybridizes in a region that is conserved among all Crypto-
sporidium species and the CrySens labelled hybridization
probe (5’-LCRed640-GTCACATTAATTGTGATCCGTAA
AG-3’) hybridizes in a polymorphic region (nucleotides 260
to 264) with various mismatches. Thermocycling and
fluorescence detection were performed by means of a
LightCycler 2.0 system (Roche Diagnostics) in a final
volume of 20 μL, using a Roche LC Faststart DNA
Master HYPROBE (Roche Diagnostics) with 0.5 μM of
each primer, 0.2 μM of hybridization probe, 0.5U of
UNG (Roche Diagnostics), and 5 μL of extracted DNA.
After applying 95 °C for 10 min, amplification was
commenced consisting of 50 cycles of 10-sec denatur-
ation at 95 °C, 15 sec of annealing at 50 °C (with a
touchdown protocol beginning at 60 °C), and 15 sec of
elongation at 72 °C. The fluorescent signal (640 nm)
was detected following the annealing step of each cycle.
Species/genotypes differentiation was based on differ-
ences in the melting temperatures of the PCR-probe
complexes, which were determined based on the extent
of complementation of the probes to the target strand
of the PCR product. For the melting curve analysis, a
quick denaturation step was performed at 95 °C
followed by a 30-sec annealing step from 45 °C to 80 °C
(ramp-up rate: 0.1 °C/s), with continuous detection
throughout the ramp up. The technique was validated
using Cryptosporidium DNA of a stool collection already
characterized at the genus level and positive controls for
C. parvum and C. hominis [12].
The five predominant human pathogenic Cryptosporid-
ium species were identified based on their melting curve
profiles (61.9 °C, 53.8 °C, 48.8 °C, 56.7 °C, and 51.8 °C for
C. parvum, C. hominis, C. felis, C. meleagridis, and C. canis,
respectively). Given that C. cuniculus, an emergent human
species, possesses the same melting curve profile as that of
C. hominis, with both species exhibiting the same DNA
sequence at the hybridization probe locus, all isolates
identified as C. hominis were then sequenced to differ-
entiate C. hominis from C. cuniculus.
For sub-genotyping analysis, DNA samples were sub-
jected to amplification of an 850-bp fragment of the
gp60 gene using a nested PCR method [19]. The total
volume of PCR mixture was 50 μL, containing 5 μL of
DNA for the primary PCR or 5 μL of the primary PCR
products, primers (outer primers: AL3531 and AL3535;
inner primers: AL3432 and AL3534) at a concentration
of 0.4 μM, 0.2 mM deoxyribonucleotide triphosphate
mix, and 1.25U of DreamTaq DNA polymerase. Each
PCR reaction was subjected to 40 cycles of 30s denatur-
ation at 95 °C, 60s annealing at 55 °C, and 60s extension
at 72 °C, with an initial 5 min denaturation at 95 °C and
a final 10 min extension at 72 °C. PCR products were vi-
sualized by electrophoresis on an ethidium bromide
stained 2 % agarose gel electrophoresis. Amplicons were
purified and sequenced in both directions with the for-
ward and reverse primers used in the secondary PCR at
a concentration of 0.32 μM. Sequencing was performed
using a BigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, USA) and an ABI PRISM 3100
Genetic Analyzer® (Applied Biosystems, USA). We ana-
lyzed the quality of the generated electrophoregrams
from each strand using 4Peaks software and compared
them with those available in the GenBank database using
the basic local alignment search tool. Subtype assign-
ment was based on the number of trinucleotide repeats
(TCA, TCG or TCT) in the coding for serine [20].
Results
For Patient #1, genotyping revealed a C. felis infection. For
Patient #2, genotyping revealed C. hominis sub-genotype
IaA13. For Patient #3, the C. parvum sub-genotype
IIaA13G1R2 was identified.
Treatment
All three patients were treated with nitazoxanide
(500 mg x 2/day for 14 days). For Patient #1, the stools
tested negative 2 weeks after treatment initiation, with
no recurrence of diarrhea observed 4 months after the
first episode. For Patient #2, a reduction of tacrolimus
was initiated and the diarrhea regressed 8 days after
treatment initiation, although 3 months after therapy
was started, his stools still tested positive. A second ad-
ministration of nitazoxanide was thus prescribed and we
requested a stool sample from his daughter for testing.
One month after the second treatment course, his stools
were tested negative for Cryptosporidium oocysts. For
Patient #3, tacrolimus was also reduced and his diarrhea
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was regressing 1 month after treatment initiation. Four
months after the second treatment course, his stools
were tested negative for Cryptosporidium oocysts.
Conclusions
We report here a series of nearly concomitant cases of
acute symptomatic cryptosporidiosis in three renal
transplant patients attending the same outpatient unit of
a Nephrology Department. The patients’ consultations
records in the Nephrology department showed that they
could have been in contact in July 2014. This possibility
of contact before the onset of symptoms suggesting a
possible nosocomial infection requires a genotyping to
explore this hypothesis. In these patients, Cryptosporid-
ium species and gp60 genotypes, which were determined
to document a possible outbreak, provided no evidence
of nosocomial transmission.
As our report demonstrates, the detection of three
different Cryptosporidium species in three cryptospor-
idiosis patients excluded the possibility of nosocomial
transmission in the Nephrology unit, where renal trans-
plant patients frequently consult and come into contact
with each other. Our findings highlight the risk of
symptomatic cryptosporidiosis in immunosuppressed
renal transplant patients. In 2014, nine out of ten pa-
tients with cryptosporidiosis diagnosed by the medical
Parasitology and Mycology laboratory of the Strasbourg
University Hospital were renal transplant patients (un-
published data). In a pediatric renal transplantation
unit, Cryptosporidium spp. was confirmed as the princi-
pal cause of diarrhea in patients between 6 months and
12 years of age following transplantation. In Poland and
India, the prevalence of Cryptosporidium spp. in renal
transplant patients was reported to be 18.8 and 20 %,
respectively [21, 22]. Cryptosporidium spp. infections
were more commonly associated with profuse watery
diarrhea in solid-organ recipients than in immunocom-
petent patients [21, 23, 24]. Our patients undergoing
combined immunosuppressive therapies exhibited watery
diarrhea for several weeks before consulting, suggesting
that the prevalence of Cryptosporidium spp. infections
is probably underestimated in renal transplant units
where screening of patients with diarrhea is not rou-
tinely performed. In all three of our patients, the symp-
toms completely resolved within 8 days to 1 month, in
line with previous reports of slower recovery duration
compared to immunocompetent patients in whom
diarrhea symptoms usually cease after 10 to 15 days
without treatment [3, 16]. Considering the role of im-
munosuppression in the appearance and persistence of
cryptosporidiosis, we opted to reduce the immunosup-
pressive regimen in two of our patients, which, in asso-
ciation with the anticryptosporidial agent, could prove
an effective method in reducing both duration and se-
verity of symptoms [3, 12, 25].
C. felis cryptosporidiosis (patient #1) is rarely diag-
nosed in France (4.8 % of all cases between 2006 and
2009 vs., 54 % for C. parvum and 36 % for C. hominis)
[5]. No contact with cats was reported, in agreement
with previous reports showing that cat ownership is
not a significant risk factor for C. felis infection and
that C. felis host specificity is not very strict, since it
was observed in cats, cattle and humans, thus render-
ing it often difficult to determine the source of infec-
tion [5, 26, 27].
C. hominis infection observed in Patient #2, is preva-
lent worldwide, and especially in developing areas, with
similar incidences to those of C. parvum infection in
most European countries, but less frequently reported
than C. parvum infection in France and the Middle-East
area [20, 24–29]. Travel-related cryptosporidiosis and
small family outbreaks have been frequently associated
with C. hominis infection, consistent with the onset of
symptoms during our patient’s trip to Africa [5]. To the
best of our knowledge, human cases of the C. hominis
IaA13 sub-genotype have only been reported in Australia,
but reports of the C. hominis genotypes present in Africa
are scarce [30].
C. parvum, the predominant species in French crypto-
sporidiosis patients, was detected in Patient #3 [5]. The
C. parvum IIaA13G1R2 genotype had previously been
reported in Sweden and Germany with no identification
of the mode of contamination [31].
Our findings confirm the need to consider cryptospor-
idiosis as a significant cause of acute persistent watery
diarrhea in immunocompromised kidney transplanted
patients. In hospitals or day-care centers, renal trans-
plant patients should be informed in order to minimize
risk of infection by handwashing and avoiding contact
with young pets, infected people and swimming pools.
Moreover, in renal transplant unit, patient with pro-
longed diarrhea should be tested for Cryptosporidium
and isolated [14, 15]. Risk of diarrhea due to Cryptospor-
idium being high for kidney transplant patients, species
identification by molecular biology is important. First, to
eliminate a possible nosocomial infection in patients
who will be often in contact during consultations in the
nephrology department; second, to determine the source
of contamination (notably animal) and eliminate it to
prevent any subsequent recontamination.
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